XIAP and Epstein-Barr virus infection: B-lymphocyte directed therapy, such as rituximab, may benefit diseases where EBV infection causes HLH (such as SAP and XIAP deficiencies) or where autoantibody production is problematic (such as APS1, or CTLA-4 haploinsufficiency) (35, 46).